Results 181 to 190 of about 30,065,898 (295)

A sustainable business ecosystem: a case study demonstrating biochar's potential

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract The need for renewable, climate‐friendly resources has become urgent as legislators worldwide have sought to find ways to cut emissions while ensuring resource security for consumers. The use of biochar could help to achieve these goals. This study examines the current state of commercial biochar production and the maturity of the related ...
Juuso Kivijakola, Eemeli Erkheikki, Viljo Lukka, Pekka Tervonen, Harri Haapasalo   +4 more
wiley   +1 more source

In the quicksand: the suspended lives of non-returnable migrants in Italy. [PDF]

Front Sociol
Cimino F, Grasso B, Perocco F.
europepmc   +1 more source

Setting up mother–infant pair lactation studies with biobanking for research according to regulatory requirements

British Journal of Clinical Pharmacology, EarlyView.
Within the ConcePTION project we set out to design two mother–infant pair studies collecting breast milk and plasma from the mother and plasma from the infant (for metformin and prednisolone) in order to demonstrate the premises and conditions for investigating potential drug transfer in association with breastfeeding.
Mats Hansson, Ida Björkgren, Jenny Svedenkrans, Helena Backman, Jarl Hellman, Linda Englund‐Ögge, Mikaela Magnusson, Inger Lindström, Andrea Wutte, Erica Sundell, Pawel Baranczewski, Laura Shaughnessy   +11 more
wiley   +1 more source

How Often Do Pharmacists End up in Court? Analysis of Civil and Criminal Case Law in Poland. [PDF]

Healthcare (Basel)
Merks P, Koziol M, Woźnicka I, Religioni U, Kaźmierczak J, Drab T, Ostrowski J, Kulka P, Sikorski S.   +8 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Civil society resistance to anti-rights mobilisation.

BMJ
McGovern T, Meng A, O'Rourke M, Athar R.
europepmc   +1 more source

Impacts of Food Adulteration and Contamination: Health, Socio-Economic, and Legislative Aspects. [PDF]

Foods
Momtaz M, Bubli SY, Khan MS.
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

The quantification and epistemology of medicines use and polypharmacy tested in an observational study

British Journal of Clinical Pharmacology, EarlyView.
Definitions of ‘medicines use’ and ‘polypharmacy’ may refer to all medicines, regular long‐term medicines or another subset. Valid definitions of medicines use should incorporate type of use (long term, short course and as needed [PRN]), changes in use (start, stop and dose change) and a description of temporal examination (cross‐sectional or ...
Lorna Pairman, Paul Chin, Matthew Doogue
wiley   +1 more source

Representation of drug addiction in Pakistani print media: A Latent Dirichlet Allocation analysis. [PDF]

PLoS One
Zahid S, Nawaz M, Zahra K.
europepmc   +1 more source